Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
643 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00514371 | A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma(TIME-2) | completed | Phase 2 / Phase 3 | 22 | Bristol-Myers SquibbINDUSTRY | 1 | Dec 7, 2015 | clinicaltrials |
| NCT01709162 | Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma | terminated | Phase 2 | 31 | Bristol-Myers SquibbINDUSTRY | 5 | Nov 30, 2015 | clinicaltrials |
| NCT00594984 | Phase I/II Combination With Irinotecan- Erbitux | completed | Phase 1 / Phase 2 | 38 | Bristol-Myers SquibbINDUSTRY | 7 | Nov 4, 2015 | clinicaltrials |
| NCT00773344 | Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin | completed | Phase 1 / Phase 2 | 25 | Bristol-Myers SquibbINDUSTRY | 1 | Nov 4, 2015 | clinicaltrials |
| NCT00780000 | Clinical Trial of Intravenous Alvespimycin in Patients With Her2 Positive Breast Cancer | terminated | Phase 2 | 4 | Bristol-Myers SquibbINDUSTRY | 0 | Nov 4, 2015 | clinicaltrials |
| NCT00284804 | A Phase II Study of MDX-060 in Subjects With Relapsed or Refractory Hodgkin's Disease | completed | Phase 2 | 74 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 12, 2015 | clinicaltrials |
| NCT00309023 | Study of BMS-663513 in Patients With Advanced Cancer | terminated | Phase 1 / Phase 2 | 115 | Bristol-Myers SquibbINDUSTRY | 3 | Oct 12, 2015 | clinicaltrials |
| NCT00546247 | A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1) | terminated | Phase 1 / Phase 2 | 26 | Bristol-Myers SquibbINDUSTRY | 2 | Oct 12, 2015 | clinicaltrials |
| NCT00550017 | A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2) | terminated | Phase 1 / Phase 2 | 39 | Bristol-Myers SquibbINDUSTRY | 3 | Oct 12, 2015 | clinicaltrials |
| NCT00612664 | Phase II, 2nd Line Melanoma - RAND Monotherapy | completed | Phase 2 | 158 | Bristol-Myers SquibbINDUSTRY | 6 | Oct 12, 2015 | clinicaltrials |
| NCT00743938 | A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC | completed | Phase 2 | 141 | Bristol-Myers SquibbINDUSTRY | 8 | Oct 12, 2015 | clinicaltrials |
| NCT00779428 | Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin | completed | Phase 2 | 6 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 12, 2015 | clinicaltrials |
| NCT00838890 | A Study of BMS-863233 in Patients With Hematologic Cancer | terminated | Phase 1 / Phase 2 | 11 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 12, 2015 | clinicaltrials |
| NCT00850577 | Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer | terminated | Phase 2 | 255 | Bristol-Myers SquibbINDUSTRY | 8 | Oct 12, 2015 | clinicaltrials |
| NCT00851045 | Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer | completed | Phase 2 | 17 | Bristol-Myers SquibbINDUSTRY | 3 | Oct 12, 2015 | clinicaltrials |
| NCT01068704 | Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer | completed | Phase 2 | 4 | Bristol-Myers SquibbINDUSTRY | 4 | Oct 12, 2015 | clinicaltrials |
| NCT01108705 | Comparison of Brivanib and Best Supportive Care (BSC) With Placebo and BSC for Treatment of Liver Cancer in Asian Patients Who Have Failed Sorafenib Treatment(BRISK-APS) | terminated | Phase 3 | 87 | Bristol-Myers SquibbINDUSTRY | 4 | Oct 12, 2015 | clinicaltrials |
| NCT01167244 | Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response | completed | Phase 2 | 11 | Bristol-Myers SquibbINDUSTRY | 1 | Oct 12, 2015 | clinicaltrials |
| NCT00633789 | Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types | completed | Phase 2 | 597 | Bristol-Myers SquibbINDUSTRY | 9 | Oct 9, 2015 | clinicaltrials |
| NCT00729664 | Multiple Ascending Dose (MDX1105-01)(Anti-PDL1) | completed | Phase 1 | 281 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 7, 2015 | clinicaltrials |
| NCT00534807 | A Study of the Interaction of Rifampin and Vinflunine in Subjects With Advanced Cancer | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Sep 1, 2015 | clinicaltrials |
| NCT00792558 | Ascending Multiple-Dose Study of BMS-817378 in Subjects With Advanced Cancers | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 2 | Sep 1, 2015 | clinicaltrials |
| NCT01750580 | Safety Study of BMS-986015 (Anti-KIR) in Combination With Ipilimumab in Subjects With Selected Advanced Tumor | completed | Phase 1 | 22 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 22, 2015 | clinicaltrials |
| NCT00798252 | Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers | completed | Phase 1 | 111 | Bristol-Myers SquibbINDUSTRY | 2 | Jul 7, 2015 | clinicaltrials |
| NCT02050594 | Ipilimumab 12-month Intensive Pharmacovigilance Protocol | completed | — | 6 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 7, 2015 | clinicaltrials |
| NCT02363868 | Healthcare Costs Among Patients With CML Receiving Dasatinib or Nilotinib in a Commercial and Medicare Population | completed | — | 186 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 7, 2015 | clinicaltrials |
| NCT01681212 | Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma | completed | Phase 2 | 21 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 11, 2015 | clinicaltrials |
| NCT00452673 | Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer | completed | Phase 1 | 52 | Bristol-Myers SquibbINDUSTRY | 3 | Mar 24, 2015 | clinicaltrials |
| NCT01120457 | First in Human Study to Determine the Safety, Tolerability and Preliminary Efficacy of an Anti-CXCR4 Antibody in Subjects With Acute Myelogenous Leukemia and Selected B-cell Cancers | completed | Phase 1 | 96 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 6, 2015 | clinicaltrials |
| NCT01629758 | Safety Study of IL-21/Anti-PD-1 Combination in the Treatment of Solid Tumors | completed | Phase 1 | 33 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00441337 | A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies(MDX1106-01) | completed | Phase 1 | 39 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 20, 2015 | clinicaltrials |
| NCT01400451 | Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) | terminated | Phase 1 | 18 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 1, 2015 | clinicaltrials |
| NCT00123487 | Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML | completed | Phase 3 | 638 | Bristol-Myers SquibbINDUSTRY | 32 | Nov 3, 2014 | clinicaltrials |
| NCT00324155 | Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma | completed | Phase 3 | 681 | Bristol-Myers SquibbINDUSTRY | 25 | Nov 3, 2014 | clinicaltrials |
| NCT01046864 | Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) | completed | Phase 1 | 49 | Bristol-Myers SquibbINDUSTRY | 3 | Sep 16, 2014 | clinicaltrials |
| NCT01489059 | Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma | completed | Phase 1 | 42 | Bristol-Myers SquibbINDUSTRY | 2 | Aug 29, 2014 | clinicaltrials |
| NCT00323882 | Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 75 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 28, 2014 | clinicaltrials |
| NCT00670189 | A Phase 1 Study of BMS-833923 (XL139) in Subjects With Advanced or Metastatic Cancer | completed | Phase 1 | 53 | Bristol-Myers SquibbINDUSTRY | 2 | Aug 15, 2014 | clinicaltrials |
| NCT01165216 | Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer | completed | Phase 1 | 15 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 22, 2014 | clinicaltrials |
| NCT01540461 | Determine the Pharmacokinetics and Safety of Brivanib in Chinese Subjects With Advanced Primary Liver Cancer (Hepatocellular Carcinoma: HCC) | completed | Phase 1 | 17 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 8, 2014 | clinicaltrials |
| NCT00920907 | Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma | completed | Phase 1 | 99 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 20, 2014 | clinicaltrials |
| NCT00623766 | Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases | completed | Phase 2 | 99 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 9, 2014 | clinicaltrials |
| NCT01471197 | Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer | terminated | Phase 2 | 9 | Bristol-Myers SquibbINDUSTRY | 5 | May 12, 2014 | clinicaltrials |
| NCT00439270 | Study of Dasatinib and Docetaxel in Metastatic Hormone Refractory Prostate Cancer | completed | Phase 1 / Phase 2 | 49 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 28, 2014 | clinicaltrials |
| NCT00796991 | Drug-Drug Interaction - 3 Arm - Carboplatin/Paclitaxel, Dacarbazine | completed | Phase 1 | 72 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00320190 | Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib | terminated | Phase 2 | 52 | Bristol-Myers SquibbINDUSTRY | 11 | Oct 30, 2013 | clinicaltrials |
| NCT00569036 | Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors | completed | Phase 1 | 63 | Bristol-Myers SquibbINDUSTRY | 1 | Aug 14, 2013 | clinicaltrials |
| NCT00971841 | Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Advanced or Recurrent Esophageal Cancer | completed | Phase 2 | 1 | Bristol-Myers SquibbINDUSTRY | 0 | Jul 26, 2013 | clinicaltrials |
| NCT00872976 | Study of Dasatinib and Bendamustine in Chronic Lymphocytic Leukemia | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 1 | Jul 22, 2013 | clinicaltrials |
| NCT00437437 | A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664) | completed | Phase 1 | 29 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 21, 2013 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials